Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Non-Current Liabilities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $336.9 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 3.89% to $336.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $336.9 million through Dec 2025, up 3.89% year-over-year, with the annual reading at $336.9 million for FY2025, 3.89% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $336.9 million at Myriad Genetics, down from $353.6 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $440.6 million in Q2 2023, with the low at $235.1 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $332.5 million, with a median of $318.0 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities plummeted 44.93% in 2022, then surged 87.41% in 2023.
  • Over 5 years, Total Non-Current Liabilities stood at $320.8 million in 2021, then dropped by 16.15% to $269.0 million in 2022, then increased by 17.17% to $315.2 million in 2023, then rose by 2.89% to $324.3 million in 2024, then rose by 3.89% to $336.9 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $336.9 million, $353.6 million, and $287.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.